Neuland Laboratories Limited has informed the Exchange regarding Change in Auditors of the company.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts less than Nifty Smallcap 250 and 7.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neuland Laboratories' Board, at its May 15, 2025 meeting, approved audited financial results for FY25 with a clean (unmodified) audit opinion from statutory auditors MSKA & Associates. Consolidated revenue fell to Rs. 1,476.8 crore from Rs. 1,558.6 crore in FY24, and net profit declined to Rs. 260.1 crore from Rs. 300.1 crore, translating to an EPS of Rs. 202.74 (vs Rs. 233.89 earlier). The dip was cushioned by an exceptional gain of Rs. 76.4 crore from the sale of an investment property in Nanakramguda, Hyderabad. The Board recommended a final dividend of Rs. 12 per share (120% on face value of Rs. 10) and re-appointed Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director for another 5 years effective June 1, 2025. M/s P.S. Rao & Associates were also appointed as new Secretarial Auditors for a 5-year term from FY26 to FY30.
Year-on-year decline in core revenue and profit may pressure the stock in the near term, but a healthy Rs. 12 dividend and clean audit signal management confidence and stable governance. Continuity of statutory auditors and a family-promoter re-appointment suggest no disruption to leadership or oversight.